TB-500 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-29. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Speer, William (1870). The oldest and the newest empire: China and the United States. Hartford, Conn., S. S. Scranton and company; Philadelphia, Parmelee & co.; [etc., etc.] Thelwall, A. S. (1839). The iniquities of the opium trade with China; being a development of the main causes which exclude the merchants of Great Britain from the advantages of an unrestricted commercial intercourse with that vast empire. With extracts from authentic documents. London : Wm. H. Allen and Co. Turner, Frederick Storrs (1876). British opium policy and its results to India and China. London, S. Low, Marston, Searle, & Rivington. Matthee RP (2005). The Pursuit of Pleasure: Drugs and Stimulants in Iranian History, 1500–1900. Princeton, New Jersey: Princeton University Press. ISBN 978-0691118550.
A police investigation into claims former Conservative MP Mark Menzies misused donors' money to pay "bad people" is dropped after he agreed to repay the money. Former Conservative minister Maria Caulfield, who lost her seat at the last election, joins Reform UK. Mark McEwan steps down as Standards Commissioner at Stormont a week after his appointment to take up the post of Deputy Chief Constable of Surrey Police. 17 September – Mason Humberstone, a member of Stevenage Borough Council, becomes the first Labour Party councillor to defect to Reform UK. 18 September – The Newham Independents win a local by-election in Plaistow South. 19 September – The Terminally Ill Adults (End of Life) Bill passes its second reading in the House of Lords. Jamie Hepburn resigns as the Scottish Government's Minister for Cabinet and Parliamentary Business following a complaint that he assaulted former Conservative leader Douglas Ross as the two were leaving the Scottish Parliament building two days earlier. Wales's Health Minister, Jeremy Miles, announces he will not stand in the 2026 Senedd election. John Allen, a councillor on Northumberland County Council, is suspended from Reform UK following allegations he made online threats to kill the prime minister. A schism breaks out between Zarah Sultana and Jeremy Corbyn over Your Party. Andy Burnham says he "isn't ruling out" a return to Westminster politics. 20 September – The Liberal Democrat conference starts in Bournemouth. Gavin Robinson launches the Democratic Unionist Party conference in Belfast.
==== 2000-2009 ==== In 2000, Teva acquired Canada-based Novopharm. In October 2003, Teva announced its intentions to acquire Sicor Inc. for $3.4 billion. Following the announcement, the acquisition was completed on January 22, 2004, which marked Teva's entry into biosimilars' market. In 2005, Teva opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim, a technology park in Jerusalem. The plant received FDA approval in early 2007. Teva entered the Japanese market in 2005 and in 2008 established a generics joint venture with Kowa. In January 2006, Teva acquired its U.S. rival Ivax Corporation for $7.4 billion. In 2008, sales totalled $11.08 billion, $13.9 billion in 2009, and in 2010 total sales rose to $16.1 billion, of which a major portion was in Europe and North America. In July 2008, Teva announced it completed the acquisition of Bentley Pharmaceuticals for its generic pharmaceutical operations in Spain for $360 million in cash. On December 23, 2008, Teva acquired Barr Pharmaceuticals for $7.5 billion, making Barr and Pliva (which Barr bought earlier) part of Teva.
== Books == The Science of Desire: The Search for the Gay Gene and the Biology of Behavior (Simon and Schuster, 1994) ISBN 0-684-80446-8 Living with Our Genes: Why They Matter More Than You Think with Peter Copeland (Anchor, 1999) ISBN 0-385-48584-0 The God Gene: How Faith Is Hardwired into our Genes (Doubleday, 2004) ISBN 0-385-50058-0
=== Historical sites === Lebanon is the home of the Historic Cragun House. Built in 1893, it was once the home of Strange Nathaniel Cragun and his family. The family travelled the world, and their house is now a living history museum full of the pieces they collected from their travels as well as original furniture from the dwelling. This Victorian home is owned and maintained by the Boone County Historical Society and serves as headquarters for the organization. The Cragun House has been added to the National Register of Historic Places. Also listed on the National Register of Historic Places are the Boone County Courthouse and Oak Hill Cemetery.
Sources: en.wikipedia.org
The cytoskeleton (cyto- meaning 'cell') is used to stabilize and preserve the form of the cells. It is a dynamic structure that maintains cell shape, protects the cell, enables cellular motion using structures such as flagella, cilia and lamellipodia, and transport within cells such as the movement of vesicles and organelles, and plays a role in cellular division. The cytoskeleton is not a skeleton in the sense that it provides the structural system for the body of an animal; rather, it serves a similar function at the cellular level.
=== Drug-induced obesity === Certain medications may cause weight gain or changes in body composition; these include insulin, sulfonylureas, thiazolidinediones, atypical antipsychotics, antidepressants, steroids, certain anticonvulsants (phenytoin and valproate), pizotifen, and some forms of hormonal contraception.
== Post-war life == At the end of the Second World War, on 8 May 1945, August Wilhelm was arrested by the U.S. Army and imprisoned in Ludwigsburg. A young German Jewish refugee started his interrogation as an American soldier. At his denazification trial (Spruchkammerverfahren) in 1948, he was asked if he had since repudiated National Socialism, and replied: "I beg your pardon?" He was thus categorized as "incriminated" by the denazification process and sentenced to two-and-a-half years' hard labour. However, as he had been confined in the Ludwigsburg internment camp since 1945, he was considered to have served his sentence. Immediately after his release, new proceedings were instituted against August Wilhelm. A court in Potsdam, in the Soviet occupation zone, issued an arrest warrant against him, but soon after that he became seriously ill and died at a hospital in Stuttgart at the age of 62 from lung cancer. He was buried in Langenburg in the cemetery of the princes of Hohenlohe-Langenburg. He was identified (in an investigation in the 1960s) as one of those who pulled the trigger in the execution of Albrecht Höhler in 1933. With his wife, Princess Alexandra of Schleswig-Holstein-Sonderburg-Glücksburg, Prince August Wilhelm had one son:
== Function == GSTK1 has been suggested to promote adiponectin multimerization in the endoplasmic reticulum (ER), but this has been contradicted by later studies. GSTK1 can prevent ER stress and ER stress-induced adiponectin down-regulation, implying that GSTK1 assists the ER’s functions. GSTK1 is located in the ER and also in the mitochondria of hepatocytes. This indicates a potential role for GSTK1 in the interaction between the two organelles; though this is poorly understood. The discovery of GSTK1 in the peroxisome has led to studies based on its function. It has been suggested that, similar to GSTA, GSTK1 may play a role in the buffering of acyl-CoA and xenobiotic-CoA and be involved in their binding activities. GSTK1 may also be responsible for the detoxification of lipid peroxides created in the peroxisome based on the peroxidase activity towards three substrates: tert-butyl hydroperoxide, cumene hydroperoxide, and 15-S-hydroperoxy-5,8,11,13-eicosatetraenoic acid.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.